Firms

Esplanade Ventures

Toronto, Ontario, Canada · Montreal, Quebec, Canada

Esplanade Ventures is a Canadian digital-health venture-capital firm with Toronto and Montreal offices, investing from seed through Series A and selectively Series B. Its current strategy favours healthcare AI software and companies commercialising in North America. The official portfolio includes Override, Neura Health, Sana Health, Cleerly, Rad AI and other healthcare and technology businesses; exit labels are preserved as historical. The firm’s own June 2021 announcement uses the Esplanade HealthTech Ventures brand and directly links the same esplanadeventures.com domain, establishing the brand bridge. It reports the inaugural Fund I closing with more than CAD21 million of commitments, without an exact corpus. Its current eight-person directory includes two advisers; former 2021 titles are not asserted current. The founder’s current biography says formed in2019, while the 2021 announcement says founded and seeded in February2020; founded is left NULL rather than silently resolving that discrepancy. Carebook’s own filed circular identifies an affiliated shareholder as Esplanade HealthTech Ventures I, G.P.; that does not establish the registered management-company suffix or a new manager identity. Exact management-company registration, underlying Override subscriber, and Fund II’s final corpus and closing date remain unverified. No third-party-only legal Inc. suffix, residual amount, fund target or internal AI-fund filter is treated as verified legal fund cash.

Founded: —
Type: Venture capital

Funds2

Esplanade HealthTech Ventures I2021-06-152021-06-15—
Firm’s June15,2021 announcement expressly confirms inaugural Fund I closing with MORE THAN CAD21M commitments. Exact final corpus and paid-in amounts unpublished; amountNULL rather than assigning the threshold or converting it to a false preciseUSD amount. June15 is the published closing announcement. First close more than a year earlier, exact day unproved. Carebook separately identifies an affiliated I,G.P. shareholder; precise closing-vehicle suffix not inferred.
Esplanade HealthTech Ventures Fund II (published programme)——
Firm’s own June2021 announcement names prospective Fund II and expects a first close later that year. Current official portfolio source uses fund2 allocations, corroborating the named programme. No accessible primary evidence establishes exact legal LP name, final closing date, corpus or payments; all cash/date fields NULL. Secondary claims of a2021 close are not converted into verified cash. Internal aifund labels are not a proven additional legal fund.